A new discovery of an ancestral fossil virus buried within everyone's genomes might provide the key to eradicating HIV.
Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.
Norway's Bionor Pharma and U.K. scientists claim they've identified a biomarker in some patients that may be connected with an improved response to a therapeutic HIV vaccine now under development.
A novel intravaginal ring to prevent HIV showed promise in pig-tailed macaque monkeys, demonstrating the benefits of sustained and controlled topical drug delivery over oral intake.
Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences' dominance in the field.
Thanks to a Series B round from Wellcome Trust and the Bill and Melinda Gates Foundation, U.K. biotech Kymab has some new vaccine research plans.
A weakness in the HIV virus exposed by scientists at the Scripps Research Institute and the International AIDS Vaccine Initiative may provide clues for designing a much-sought HIV vaccine.
Powered by sales that averaged more than $25 million a day for brand-new hep C drug Sovaldi, Gilead Sciences beat all expectations, with quarterly sales that nearly doubled and profits that tripled in the first quarter.
Daktari Diagnostics achieved another milestone in its quest to raise $30 million for its groundbreaking HIV test. The company recently brought in $13 million in equity, moving it closer to realizing its original fundraising goal, the Boston Business Journal reports.
ViiV Healthcare has inked a deal with the Medicines Patent Pool to speed access to cheap copies of Tivicay (dolutegravir) in developing countries.